Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octohydroaminoacridine Succinate Phase III in Mild-to-Moderate Alzheimer's Disease
NCT03283059Phase 3Unknown
- Sponsor
- Shanghai Mental Health Center
- Start
- Aug 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of octohydroaminoacridine in Alzheimer's disease (AD), sponsored by Shanghai Mental Health Center. Status: unknown.
02
Drugs
octohydroaminoacridine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03283059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283059.